Three-in-one DNA nanowheels for simultaneous tumor regression and drug resistance prevention in breast cancer model

Ping Li , Chun-Feng Feng , Peng-Fei Lyu , Fei Liu , Hui-Sheng Li , Li-Qun Zhang
{"title":"Three-in-one DNA nanowheels for simultaneous tumor regression and drug resistance prevention in breast cancer model","authors":"Ping Li ,&nbsp;Chun-Feng Feng ,&nbsp;Peng-Fei Lyu ,&nbsp;Fei Liu ,&nbsp;Hui-Sheng Li ,&nbsp;Li-Qun Zhang","doi":"10.1016/j.asems.2024.100104","DOIUrl":null,"url":null,"abstract":"<div><p>Herein, we proposed novel three-in-one DNA nanowheels with simultaneous chemo and gene therapy to treat tumor, especially to prevent simultaneous drug resistance, which could be disassembled <em>via</em> a cascaded hybridization reactions triggered by the highly expressed microRNA in cancer cells for smart and efficient cancer therapy. Typically, with breast cancer as a model, microRNA 21 could trigger the self-disassembly of DNA nanowheel 1 <em>via</em> hybridization with a specially designed oligonucleotide (anti-microRNA 21) in DNA nanowheel 1, releasing another special oligonucleotide (Contact sequence) to trigger the self-disassembly of DNA nanowheel 2 with releasing of a special oligonucleotide (anti-Contact sequence) to trigger the self-disassembly of DNA nanowheel 1 cyclically, and thus the cascaded hybridization reactions with three-in-one anti-cancer functions could be generated based on three main therapeutic effects <em>via</em> releasing doxorubicin to inhibit macromolecular biosynthesis, antisense oligonucleotide of microRNA 21 to activate the apoptotic cell pathway and antisense oligonucleotide of MDR1 to prevent the drug resistance respectively. As expected, the proposed method showed improved therapeutic efficacy on the cancer cells with about 80% apoptosis ratio, especially on the drug resistant cancer cells with about 75% apoptosis ratio, compared with that in the conventional anti-cancer systems of about 70% on cancer cells and below 40% on drug resistant cancer cells, respectively. Most importantly, this strategy opened the door for generation of complex functional DNA-based structures for target triggering drugs releasing system combining with chemo- and gene-therapy to generate tumor regression and prevent drug resistance with an optimized therapeutic efficacy, providing a new avenue for efficient cancer treatment, especially drug resistant cancers.</p></div>","PeriodicalId":100036,"journal":{"name":"Advanced Sensor and Energy Materials","volume":"3 3","pages":"Article 100104"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773045X24000153/pdfft?md5=ac5e863c59149740a770207108aac21b&pid=1-s2.0-S2773045X24000153-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Sensor and Energy Materials","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2773045X24000153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Herein, we proposed novel three-in-one DNA nanowheels with simultaneous chemo and gene therapy to treat tumor, especially to prevent simultaneous drug resistance, which could be disassembled via a cascaded hybridization reactions triggered by the highly expressed microRNA in cancer cells for smart and efficient cancer therapy. Typically, with breast cancer as a model, microRNA 21 could trigger the self-disassembly of DNA nanowheel 1 via hybridization with a specially designed oligonucleotide (anti-microRNA 21) in DNA nanowheel 1, releasing another special oligonucleotide (Contact sequence) to trigger the self-disassembly of DNA nanowheel 2 with releasing of a special oligonucleotide (anti-Contact sequence) to trigger the self-disassembly of DNA nanowheel 1 cyclically, and thus the cascaded hybridization reactions with three-in-one anti-cancer functions could be generated based on three main therapeutic effects via releasing doxorubicin to inhibit macromolecular biosynthesis, antisense oligonucleotide of microRNA 21 to activate the apoptotic cell pathway and antisense oligonucleotide of MDR1 to prevent the drug resistance respectively. As expected, the proposed method showed improved therapeutic efficacy on the cancer cells with about 80% apoptosis ratio, especially on the drug resistant cancer cells with about 75% apoptosis ratio, compared with that in the conventional anti-cancer systems of about 70% on cancer cells and below 40% on drug resistant cancer cells, respectively. Most importantly, this strategy opened the door for generation of complex functional DNA-based structures for target triggering drugs releasing system combining with chemo- and gene-therapy to generate tumor regression and prevent drug resistance with an optimized therapeutic efficacy, providing a new avenue for efficient cancer treatment, especially drug resistant cancers.

在乳腺癌模型中同时实现肿瘤消退和抗药性预防的三合一 DNA 纳米轮
在此,我们提出了新型三合一DNA纳米轮,可同时进行化疗和基因治疗以治疗肿瘤,特别是防止同时产生耐药性,该纳米轮可通过癌细胞中高表达的microRNA引发的级联杂交反应进行分解,从而实现智能高效的癌症治疗。通常情况下,以乳腺癌为例,microRNA 21 可以通过与 DNA 纳米轮 1 中特殊设计的寡核苷酸(抗 microRNA 21)杂交触发 DNA 纳米轮 1 的自组装,释放另一种特殊寡核苷酸(接触序列)触发 DNA 纳米轮 2 的自组装,同时释放一种特殊寡核苷酸(抗接触序列)循环触发 DNA 纳米轮 1 的自组装、通过释放抑制大分子生物合成的多柔比星、激活细胞凋亡途径的 microRNA 21 反义寡核苷酸和防止耐药性的 MDR1 反义寡核苷酸,分别产生具有三合一抗癌功能的级联杂交反应。正如预期的那样,与传统抗癌系统对癌细胞的凋亡率约为 70% 和对耐药癌细胞的凋亡率低于 40% 相比,该方法对癌细胞的疗效有所提高,凋亡率约为 80%,尤其是对耐药癌细胞的凋亡率约为 75%。最重要的是,这种策略为生成复杂的 DNA 功能结构靶向触发药物释放系统打开了一扇大门,它与化疗和基因治疗相结合,以优化的疗效产生肿瘤消退和防止耐药性,为高效治疗癌症,尤其是耐药性癌症提供了一条新途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信